scholarly journals Alternative processing of the sarco/endoplasmic reticulum Ca2+-ATPase transcripts during muscle differentiation is a specifically regulated process

1996 ◽  
Vol 317 (3) ◽  
pp. 647-651 ◽  
Author(s):  
Ludo VAN DEN BOSCH ◽  
Luc MERTENS ◽  
Yvon CAVALOC ◽  
Martha PETERSON ◽  
Frank WUYTACK ◽  
...  

Expression of the muscle-specific 2a isoform of the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA2) requires activation of an otherwise inefficient splice process at the 3´-end of the primary gene transcript. We provide evidence that SERCA2 splicing is a specifically regulated process, rather than the result of an increase in general splice efficiency or a decrease in polyadenylation efficiency at the 5´-most polyadenylation site. This is indicated by the fact that changes in general splice and polyadenylation efficiency, as observed during B-cell maturation, did not affect SERCA2 splicing. Furthermore, expression and overexpression studies did not support the hypothesis that changes in the level of the alternative splice factor ASF/SF2 or other arginine and serine rich proteins are sufficient to obtain the regulation of muscle- and neuronal-specific splicing.

Science ◽  
2019 ◽  
Vol 366 (6470) ◽  
pp. eaay7199 ◽  
Author(s):  
Kevin O. Saunders ◽  
Kevin Wiehe ◽  
Ming Tian ◽  
Priyamvada Acharya ◽  
Todd Bradley ◽  
...  

2021 ◽  
Vol 12 ◽  
pp. 204062072198958
Author(s):  
Larysa Sanchez ◽  
Alexandra Dardac ◽  
Deepu Madduri ◽  
Shambavi Richard ◽  
Joshua Richter

Outcomes of patients with multiple myeloma (MM) who become refractory to standard therapies are particularly poor and novel agents are greatly needed to improve outcomes in such patients. B-cell maturation antigen (BCMA) has become an important therapeutic target in MM with three modalities of treatment in development including antibody–drug conjugates (ADCs), bispecific T-cell engagers (BITEs), and chimeric antigen receptor (CAR) T-cell therapies. Early clinical trials of anti-BCMA immunotherapeutics have demonstrated extremely promising results in heavily pretreated patients with relapsed/refractory MM (RRMM). Recently, belantamab mafodotin was the first anti-BCMA therapy to obtain approval in relapsed/refractory MM. This review summarizes the most updated efficacy and safety data from clinical studies of BCMA-targeted therapies with a focus on ADCs and BITEs. Additionally, important differences among the BCMA-targeted treatment modalities and their clinical implications are discussed.


1999 ◽  
Vol 11 (10) ◽  
pp. 1663-1671 ◽  
Author(s):  
Xuejun Shen ◽  
Grazyna Bozek ◽  
Carl A. Pinkert ◽  
Ursula Storb

2010 ◽  
Vol 37 (8) ◽  
pp. 3747-3755 ◽  
Author(s):  
Shaoli Deng ◽  
Tao Yuan ◽  
Xiaoxing Cheng ◽  
Rui Jian ◽  
Jing Jiang

Sign in / Sign up

Export Citation Format

Share Document